Novo led the sustainable materials producer’s series C round, three years after a round backed by investors including Ginkgo Bioworks.
US-based bioengineering technology provider Genomatica has closed a $118m series C round led by pharmaceutical firm Novo.
Casdin Capital, Nicholas Investment Partners, Tenere Capital, Tharsis Capital and Viking Global Investors filled out the participants in the round.
Founded in 2000, Genomatica produces sustainable chemicals which leverage plant and waste-derived raw materials to replace traditional materials or chemicals.
Microbe engineering group Ginkgo Bioworks had taken part in a $90m round for the company in 2018 that was led by Casdin…
